Audit: QRS - Black Chokeberry for Health & Longevity
Audit conducted on 13/10/2026 15:28 using AI4L + evidence-mcp / Wonder 1.0
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 88 |
| Failed | 0 |
| N/A | 6 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All QRS statements trace to ER Conclusion, Expected Benefits, Risks, Protocol and Monitoring passages. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedged wording is retained, e.g. ‘remain possible’ (QRS line 433) and ‘No established target’ (QRS lines 584-631). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No ER caution is upgraded or downgraded; pooled result is stated as ‘no clear overall benefit’ (QRS line 433), matching ER Conclusion. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefits, risks, contraindications and interactions stay in their ER categories (QRS lines 518-565, 534-548). |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, NCT numbers, study names or brand names appear in QRS body content. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution beyond the ER is introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Wording mirrors the ER’s restrained, inconsistent-evidence framing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Plain, factual wording throughout the sheet. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Studied amounts and measures are presented without prescriptive instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Footer states ‘Not medical advice’ (QRS lines 667-670); no advice phrasing in body. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is presented as studied amounts, tiers and measures, not recommendations. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the QRS. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | At-a-glance uses plain terms (QRS line 433); body labels are the ER’s own benefit/marker names. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Single-sheet compact layout with short tier lists and tables. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct reader address anywhere in the QRS. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing is health- and longevity-oriented (QRS lines 417, 433). |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol and monitoring detail suits proactive, effort-willing readers. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No general-population simplification or contrary framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Benefit/risk weighting follows the ER Conclusion for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Uses ‘Longevity’/’longevity-related’ (QRS lines 417, 433); ‘anti-aging’ does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial route/clinical terms such as ‘pill’ or ‘shot’ appear. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and Marker/Target/Why headers match (QRS lines 440, 477, 519, 537, 543, 554, 568, 573-575, 643). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template spans are present, with marker_# and qualitative_item_# correctly expanded to numbered spans (QRS lines 21-660). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Non-checklist spans (website spans, footer, styles) are unchanged from the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No top-level ER section is empty; empty benefit/risk tiers are governed by items 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | QRS labels reuse ER bold labels, e.g. ‘Extract amounts studied’, ‘Juice amount studied’, ‘Timing’ (ER Protocol; QRS lines 444-466). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker and tier labels copy ER wording verbatim (QRS lines 523-529, 581-631, 647-659). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters appear in the QRS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content fits the one-page template budget: three protocol cells, three time cells, five markers, five qualitative items. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is the first element after <!doctype html> (QRS lines 1-14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML block is delimited by — lines at QRS lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Metadata sits inside an HTML comment and renders nowhere on the sheet. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values are trimmed; the only quoted value, duration, contains a colon (QRS lines 4-12). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename at QRS line 4 matches the ER frontmatter filename. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.10.8 at QRS line 5 matches QRS.md version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-1013-1520 at QRS line 6 follows YYYY-MMDD-HHMM. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Wonder at QRS line 7. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Nickname is the single word ‘Wonder’ (QRS line 7). |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Wonder 1.0 at QRS line 8. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Full name is nickname plus version only: ‘Wonder 1.0’. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename at QRS line 9 matches the audited file name. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values are trimmed; the only quoted value, duration, contains a colon (QRS lines 4-12). |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | page_title is canonical_topic plus ‘ - Quick Reference Sheet’, entity-encoded (QRS line 22). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic equals ER canonical_topic, entity-encoded (QRS line 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date 10/13/2026 reformats qrs_creation_date (QRS line 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model is ‘Wonder 1.0’ (QRS line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only template title and subline (QRS lines 415-428). |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with what the fruit is and its forms/uses before any verdict (QRS line 433). |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER Conclusion: individual-trial signals, pooled null result, few harms (QRS line 433). |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 57 words, within the 70-word limit. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each statement maps to ER Conclusion/Motivation passages. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; ‘thinking speed’ and ‘blood-vessel function’ are plain terms. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER ‘Populations who should avoid’ under Key Interactions & Contraindications. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Three stop items match the ER avoid list (QRS line 539). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each stop item is an <li> element (QRS line 539). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Items are bare facts with no trailing rationale or dash clauses (QRS line 539). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The surgery/platelet-active qualifier from the ER is preserved (QRS line 539). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation is carried into the items. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | ER identifies avoid populations and the section is populated accordingly. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not left empty: [stop_items] lists three items at QRS line 539. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER Key Interactions & Contraindications bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Six caution items match ER interactions and none duplicates a contraindication (QRS line 545). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each caution item is an <li> element (QRS line 545). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Items carry no trailing explanations or dash clauses (QRS line 545). |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists from ER bullets are preserved in parentheses (QRS line 545). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation is carried into the items. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | ER identifies interactions and the section is populated accordingly. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not left empty: [caution_items] lists six items at QRS line 545. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from ER Therapeutic Protocol amounts and timing. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Three action cells cover extract amounts, juice/powder amounts and timing (QRS lines 441-474). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER Protocol names more than three distinct actionable aspects and all three action sets are used (QRS lines 441-474). |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All action label/value/sub spans carry ER-derived content (QRS lines 441-474). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Time cells cover vascular, psychomotor and metabolic aspects from ER trial durations (QRS lines 480-514). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Medium-tier vascular and psychomotor effects precede Low-tier metabolic markers. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides at least three time-to-effect aspects and all three time sets are used (QRS lines 480-514). |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All time label/value/sub spans carry ER-derived content (QRS lines 480-514). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information (ER Practical Considerations and trial durations), so the removal condition does not apply. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from ER Expected Benefits tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | benefits_high/medium/low/speculative spans are used as specified (QRS lines 521-530). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Benefit items are bare names with no sizes, qualifiers or citations (QRS lines 523-529). |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content is retained in benefit items. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high is empty with display:none, as no High benefit exists in the ER (QRS line 521). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from ER Potential Risks & Side Effects tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | risks_high/medium/low/speculative spans are used as specified (QRS lines 556-563). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Risk items are bare names with no frequencies or citations (QRS lines 559-562). |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content is retained in risk items. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium are empty with display:none, matching the ER (QRS lines 556-557). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from ER Monitoring Protocol & Defining Success table. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All five ER biomarkers are listed (QRS lines 579-633). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | monitoring_cadence states baseline, 8-12 week repeat and 6-12 month interval (QRS line 638). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from ER qualitative markers under Monitoring. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are listed (QRS lines 647-659). |
Issues 13/10/2026 15:28
Pass rate 100.00%. No issues found.
Issues 13/10/2026 15:25
- 1.1 — Dose trials misstated: QRS action_1_sub at line 450 states “Separate trials used 90 mg, 150 mg, or 500 mg daily”; the ER Therapeutic Protocol states 90 mg and 150 mg were separate groups in the single Ahles et al. cognition trial, with 500 mg in a separate trial.
- 4.2 / 4.3 — Protocol labels not verbatim: QRS action labels at lines 444 and 455 read “Extract amount studied” and “Juice or powder studied”; the ER bold labels are “Extract amounts studied”, “Higher extract amount studied”, “Juice amount studied”, and “Whole-fruit powder studied”.
Fixes 13/10/2026 15:25
- 1.1 — Dose trials misstated: Changed action_1_sub from “Separate trials used 90 mg, 150 mg, or 500 mg daily” to “90 mg and 150 mg as separate groups; 500 mg in a separate trial”.
- 4.2 / 4.3 — Protocol labels not verbatim: Changed action_1_label to “Extract amounts studied / Higher extract amount studied” and action_2_label to “Juice amount studied / Whole-fruit powder studied”, using the ER bold labels verbatim.
Issues 13/10/2026 15:22
- 1.1 — Studied doses stated as range: QRS line 447 states “90–500 mg daily”; ER lines 284–285 studied only discrete 90 mg, 150 mg, and 500 mg daily doses, so intermediate doses are implied but untested.
- 12.5 — Empty High benefits placeholder: QRS lines 521–523 hide the High tier but retain the literal placeholder “[benefits_high]” instead of empty content.
- 13.5 — Empty risk tiers placeholder: QRS lines 558–563 hide the High and Medium tiers but retain the literal placeholders “[risks_high]” and “[risks_medium]” instead of empty content.
Fixes 13/10/2026 15:22
- 1.1 — Studied doses stated as range: Changed Action 1 value from “90–500 mg daily” to “90 mg, 150 mg, or 500 mg daily” to match the discrete doses studied in the ER.
- 12.5 — Empty High benefits placeholder: Emptied the hidden benefits_high span, removing the literal “[benefits_high]” placeholder while keeping display:none.
- 13.5 — Empty risk tiers placeholder: Emptied the hidden risks_high and risks_medium spans, removing the literal “[risks_high]” and “[risks_medium]” placeholders while keeping display:none.